

TDMS No. 20310 - 03

Test Type: 26-39 WEEKS

Route: GAVAGE

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

AZT+3TC combination

CAS Number: AZT3TCCOMBO

Date Report Requested: 05/04/2010

Time Report Requested: 13:35:32

First Dose M/F: 12/22/06 / NA

Lab: NCTR

C Number: C20310B
Lock Date: 04/20/2010
Cage Range: ALL
Date Range: ALL
Reasons For Removal: ALL
Removal Date Range: ALL
Treatment Groups: Include ALL
Study Gender: Male
TDMSE Version: 2.2.0

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE	Vehicle	AZT 60	3TC 37.5	NVP 10.5	AZT 60 3TC 37.5	A20,3T12.5,NV3.5
---------------------------------------	---------	--------	----------	----------	-----------------	------------------

Disposition Summary

Animals Initially In Study	25	25	25	26	25	25
Early Deaths						
Moribund Sacrifice	1	2			1	
Natural Death	1	1	1	4		
Survivors						
Moribund Sacrifice	1	2			2	
Natural Death	2	2	1		1	1
Terminal Sacrifice	20	18	23	22	21	24
Animals Examined Microscopically	25	25	25	26	25	25

ALIMENTARY SYSTEM

Intestine Large, Cecum Adenoma	(22)	(22)	(24)	(22) 1 (5%)	(24)	(24)
Lymphoma Malignant		1 (5%)				
Intestine Large, Colon Lymphoma Malignant	(22)	(22)	(25)	(23)	(24)	(24)
Intestine Large, Rectum Lymphoma Malignant	(22)	(22)	(23)	(22)	(24)	(24)
Lymphoma Malignant		1 (5%)				
Intestine Small, Duodenum Leiomyosarcoma	(23) 1 (4%)	(22)	(23)	(22)	(24)	(24)
Lymphoma Malignant						
Intestine Small, Jejunum Adenocarcinoma	(23) 1 (4%)	(22)	(23)	(22)	(24)	(24)
Liver	(25)	(24)	(25)	(25)	(25)	(25)
Hemangiosarcoma					1 (4%)	
Hepatocellular Adenoma	1 (4%)	4 (17%)	2 (8%)	2 (8%)	7 (28%)	4 (16%)
Hepatocellular Adenoma, Multiple		4 (17%)	1 (4%)		2 (8%)	3 (12%)
Hepatocellular Carcinoma		1 (4%)				2 (8%)
Hepatocellular Carcinoma, Multiple					1 (4%)	
Histiocytic Sarcoma					1 (4%)	
Leukemia Granulocytic						1 (4%)
Lymphoma Malignant	1 (4%)	2 (8%)			2 (8%)	
Sarcoma, Metastatic, Uncertain Primary Site			1 (4%)			

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20310 - 03

Test Type: 26-39 WEEKS

Route: GAVAGE

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

AZT+3TC combination

CAS Number: AZT3TCCOMBO

Date Report Requested: 05/04/2010

Time Report Requested: 13:35:32

First Dose M/F: 12/22/06 / NA

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE	Vehicle	AZT 60	3TC 37.5	NVP 10.5	AZT 60 3TC 37.5	A20,3T12.5,NV3.5
Capsule, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung			1 (4%)			
Mesentery	(3)	(0)	(0)	(1)	(2)	(1)
Fibrosarcoma					1 (50%)	
Hemangiosarcoma						1 (100%)
Leiomyosarcoma, Metastatic, Intestine Small, Duodenum	1 (33%)					
Sarcoma	1 (33%)			1 (100%)		
Pancreas	(24)	(23)	(25)	(25)	(24)	(25)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung			1 (4%)			
Leiomyosarcoma, Metastatic, Intestine Small, Duodenum	1 (4%)					
Lymphoma Malignant						
Sarcoma, Metastatic, Tissue Nos	1 (4%)					
Sarcoma, Metastatic, Uncertain Primary Site			1 (4%)			
Salivary Glands	(25)	(23)	(25)	(25)	(24)	(25)
Leukemia Granulocytic						1 (4%)
Stomach, Forestomach	(25)	(23)	(25)	(23)	(24)	(25)
Stomach, Glandular	(23)	(22)	(24)	(22)	(24)	(24)
Lymphoma Malignant						
CARDIOVASCULAR SYSTEM						
Blood Vessel	(25)	(24)	(25)	(25)	(24)	(25)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung			1 (4%)			
Lymphoma Malignant	1 (4%)	2 (8%)			2 (8%)	
Heart	(25)	(25)	(25)	(25)	(24)	(25)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung			1 (4%)			
Histiocytic Sarcoma				1 (4%)		
Lymphoma Malignant	1 (4%)	2 (8%)			2 (8%)	
ENDOCRINE SYSTEM						

a - Number of animals examined microscopically at site and number of animals with lesion

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE	Vehicle	AZT 60	3TC 37.5	NVP 10.5	AZT 60 3TC 37.5	A20,3T12.5,NV3.5
Adrenal Cortex	(25)	(24)	(25)	(25)	(23)	(25)
Adrenal Medulla	(25)	(23)	(25)	(23)	(21)	(25)
Lymphoma Malignant						
Pheochromocytoma Benign						
Islets, Pancreatic	(24)	(24)	(25)	(25)	(24)	(25)
Parathyroid Gland	(23)	(21)	(24)	(18)	(19)	(23)
Pituitary Gland	(24)	(22)	(25)	(25)	(24)	(25)
Lymphoma Malignant					1 (4%)	
Thyroid Gland	(25)	(23)	(25)	(23)	(23)	(25)

GENERAL BODY SYSTEM

Tissue NOS	(1)	(0)	(1)	(3)	(0)	(0)
Abdominal, Sarcoma	1 (100%)		1 (100%)	1 (33%)		
Thoracic, Histiocytic Sarcoma				1 (33%)		

GENITAL SYSTEM

Epididymis	(25)	(23)	(25)	(25)	(24)	(25)
Sarcoma, Metastatic, Uncertain Primary Site			1 (4%)			
Preputial Gland	(25)	(24)	(25)	(25)	(24)	(25)
Squamous Cell Carcinoma						
Squamous Cell Papilloma						
Prostate	(25)	(23)	(25)	(25)	(24)	(25)
Seminal Vesicle	(25)	(23)	(24)	(25)	(24)	(25)
Sarcoma, Metastatic, Uncertain Primary Site			1 (4%)			
Testes	(25)	(24)	(24)	(25)	(24)	(25)

HEMATOPOIETIC SYSTEM

Bone Marrow	(23)	(24)	(24)	(25)	(24)	(25)
Leukemia Granulocytic						1 (4%)
Lymphoma Malignant		1 (4%)			2 (8%)	
Lymph Node	(2)	(2)	(1)	(1)	(2)	(3)

a - Number of animals examined microscopically at site and number of animals with lesion

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE	Vehicle	AZT 60	3TC 37.5	NVP 10.5	AZT 60 3TC 37.5	A20,3T12.5,NV3.5
Sarcoma, Metastatic, Uncertain Primary Site			1 (100%)			
Axillary, Lymphoma Malignant		1 (50%)			2 (100%)	
Cervical, Lymphoma Malignant					1 (50%)	
Inguinal, Lymphoma Malignant		1 (50%)				
Lumbar, Leukemia Granulocytic						1 (33%)
Lumbar, Lymphoma Malignant					2 (100%)	
Mediastinal, Lymphoma Malignant		1 (50%)				
Mediastinal, Sarcoma, Metastatic, Tissue Nos	1 (50%)					
Mediastinal, Sarcoma, Metastatic, Uncertain Primary Site			1 (100%)			
Pancreatic, Lymphoma Malignant	1 (50%)	1 (50%)				
Popliteal, Leukemia Granulocytic						1 (33%)
Popliteal, Lymphoma Malignant						
Renal, Lymphoma Malignant	1 (50%)	2 (100%)				
Lymph Node, Mandibular	(25)	(23)	(25)	(25)	(24)	(25)
Leukemia Granulocytic						1 (4%)
Lymphoma Malignant	1 (4%)	2 (9%)			2 (8%)	
Lymph Node, Mesenteric	(24)	(23)	(25)	(25)	(24)	(25)
Leukemia Granulocytic						1 (4%)
Lymphoma Malignant		1 (4%)			2 (8%)	
Sarcoma, Metastatic, Tissue Nos	1 (4%)					
Sarcoma, Metastatic, Uncertain Primary Site			1 (4%)			
Spleen	(25)	(23)	(24)	(25)	(24)	(25)
Hemangiosarcoma					1 (4%)	
Leukemia Granulocytic						1 (4%)
Lymphoma Malignant	1 (4%)	2 (9%)			2 (8%)	
Thymus	(24)	(22)	(24)	(23)	(22)	(25)
Leukemia Granulocytic						1 (4%)
Lymphoma Malignant	1 (4%)	2 (9%)			2 (9%)	
Sarcoma, Metastatic, Uncertain Primary Site			1 (4%)			
INTEGUMENTARY SYSTEM						
Skin	(25)	(25)	(25)	(25)	(24)	(25)
Lymphoma Malignant						

a - Number of animals examined microscopically at site and number of animals with lesion

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE	Vehicle	AZT 60	3TC 37.5	NVP 10.5	AZT 60 3TC 37.5	A20,3T12.5,NV3.5
Osteosarcoma, Metastatic, Bone						
Squamous Cell Papilloma						
MUSCULOSKELETAL SYSTEM						
Bone	(3)	(1)	(1)	(1)	(0)	(0)
Osteosarcoma	1 (33%)					
Cranium, Neuroblastoma, Metastatic, Nose						
Cranium, Osteosarcoma			1 (100%)			
Humerus, Osteosarcoma	1 (33%)					
Pelvis, Osteosarcoma		1 (100%)		1 (100%)		
Rib, Osteosarcoma						
Tibia, Osteosarcoma	1 (33%)					
Bone, Femur	(25)	(25)	(25)	(25)	(25)	(25)
Osteosarcoma			1 (4%)			
Skeletal Muscle	(3)	(2)	(1)	(0)	(0)	(0)
Leiomyosarcoma, Metastatic, Intestine Small, Duodenum	1 (33%)					
Lymphoma Malignant		1 (50%)				
Rhabdomyosarcoma		1 (50%)				
Diaphragm, Sarcoma, Metastatic, Tissue Nos	1 (33%)					
Diaphragm, Sarcoma, Metastatic, Uncertain Primary Site			1 (100%)			
NERVOUS SYSTEM						
Brain, Brain Stem	(25)	(24)	(25)	(25)	(24)	(24)
Lymphoma Malignant		1 (4%)			1 (4%)	
Brain, Cerebellum	(25)	(24)	(25)	(25)	(24)	(24)
Lymphoma Malignant					1 (4%)	
Brain, Cerebrum	(25)	(24)	(25)	(25)	(24)	(25)
Leukemia Granulocytic						1 (4%)
Lymphoma Malignant		1 (4%)			1 (4%)	
Olfactory Lobe, Neuroblastoma, Metastatic, Nose						

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20310 - 03

Test Type: 26-39 WEEKS

Route: GAVAGE

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

AZT+3TC combination

CAS Number: AZT3TCCOMBO

Date Report Requested: 05/04/2010

Time Report Requested: 13:35:32

First Dose M/F: 12/22/06 / NA

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE	Vehicle	AZT 60	3TC 37.5	NVP 10.5	AZT 60 3TC 37.5	A20,3T12.5,NV3.5
Spinal Cord, Thoracic	(1)	(0)	(0)	(0)	(0)	(0)
RESPIRATORY SYSTEM						
Lung	(25)	(24)	(25)	(25)	(24)	(25)
Alveolar/Bronchiolar Adenoma			1 (4%)	1 (4%)		
Alveolar/Bronchiolar Carcinoma		1 (4%)	1 (4%)			
Histiocytic Sarcoma				1 (4%)		
Lymphoma Malignant	1 (4%)	3 (13%)			3 (13%)	
Osteosarcoma, Metastatic, Bone	1 (4%)					
Nose	(25)	(25)	(25)	(25)	(25)	(25)
Lymphoma Malignant					1 (4%)	
Neuroblastoma						
Osteosarcoma		1 (4%)				
SPECIAL SENSES SYSTEM						
Eye	(22)	(22)	(23)	(23)	(24)	(24)
Harderian Gland	(25)	(22)	(25)	(25)	(24)	(25)
Adenoma			1 (4%)	1 (4%)		1 (4%)
Carcinoma			1 (4%)			
Neuroblastoma, Metastatic, Nose						
URINARY SYSTEM						
Kidney	(25)	(24)	(25)	(25)	(24)	(25)
Leukemia Granulocytic						1 (4%)
Lymphoma Malignant	1 (4%)	1 (4%)			2 (8%)	
Capsule, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung			1 (4%)			
Urinary Bladder	(25)	(24)	(25)	(25)	(24)	(25)
Sarcoma				1 (4%)		

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

TDMS No. 20310 - 03

Test Type: 26-39 WEEKS

Route: GAVAGE

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

AZT+3TC combination

CAS Number: AZT3TCCOMBO

Date Report Requested: 05/04/2010

Time Report Requested: 13:35:32

First Dose M/F: 12/22/06 / NA

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE	Vehicle	AZT 60	3TC 37.5	NVP 10.5	AZT 60 3TC 37.5	A20,3T12.5,NV3.5
SYSTEMIC LESIONS						
Multiple Organ	*(25)	*(25)	*(25)	*(26)	*(25)	*(25)
Histiocytic Sarcoma				1 (4%)	1 (4%)	
Leukemia Granulocytic						1 (4%)
Lymphoma Malignant	1 (4%)	3 (12%)			3 (12%)	

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE

AZT40,3TC25,NVP7

A60,3T37.5,N10.5

Disposition Summary

Animals Initially In Study	25	25
Early Deaths		
Moribund Sacrifice		
Natural Death		1
Survivors		
Moribund Sacrifice	1	1
Natural Death		
Terminal Sacrifice	24	23
Animals Examined Microscopically	23	24

ALIMENTARY SYSTEM

Intestine Large, Cecum	(23)	(23)
Adenoma		
Lymphoma Malignant	1 (4%)	
Intestine Large, Colon	(23)	(23)
Lymphoma Malignant	1 (4%)	1 (4%)
Intestine Large, Rectum	(23)	(23)
Lymphoma Malignant		
Intestine Small, Duodenum	(23)	(23)
Leiomyosarcoma		
Lymphoma Malignant		1 (4%)
Intestine Small, Jejunum	(23)	(23)
Adenocarcinoma		
Liver	(23)	(23)
Hemangiosarcoma		
Hepatocellular Adenoma	5 (22%)	7 (30%)
Hepatocellular Adenoma, Multiple	2 (9%)	2 (9%)
Hepatocellular Carcinoma	2 (9%)	
Hepatocellular Carcinoma, Multiple		1 (4%)
Histiocytic Sarcoma		
Leukemia Granulocytic		
Lymphoma Malignant	1 (4%)	1 (4%)
Sarcoma, Metastatic, Uncertain Primary Site		

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20310 - 03

Test Type: 26-39 WEEKS

Route: GAVAGE

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

AZT+3TC combination

CAS Number: AZT3TCCOMBO

Date Report Requested: 05/04/2010

Time Report Requested: 13:35:32

First Dose M/F: 12/22/06 / NA

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE	AZT40,3TC25,NVP7	A60,3T37.5,N10.5
---------------------------------------	------------------	------------------

Capsule, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		
Mesentery	(2)	(0)
Fibrosarcoma		
Hemangiosarcoma		
Leiomyosarcoma, Metastatic, Intestine Small, Duodenum		
Sarcoma		
Pancreas	(23)	(23)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		
Leiomyosarcoma, Metastatic, Intestine Small, Duodenum		
Lymphoma Malignant		1 (4%)
Sarcoma, Metastatic, Tissue Nos		
Sarcoma, Metastatic, Uncertain Primary Site		
Salivary Glands	(23)	(23)
Leukemia Granulocytic		
Stomach, Forestomach	(23)	(23)
Stomach, Glandular	(23)	(23)
Lymphoma Malignant	1 (4%)	

CARDIOVASCULAR SYSTEM

Blood Vessel	(23)	(24)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		
Lymphoma Malignant	1 (4%)	
Heart	(23)	(24)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		
Histiocytic Sarcoma		
Lymphoma Malignant		

ENDOCRINE SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20310 - 03

Test Type: 26-39 WEEKS

Route: GAVAGE

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

AZT+3TC combination

CAS Number: AZT3TCCOMBO

Date Report Requested: 05/04/2010

Time Report Requested: 13:35:32

First Dose M/F: 12/22/06 / NA

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE AZT40,3TC25,NVP7 A60,3T37.5,N10.5

Adrenal Cortex	(23)	(23)
Adrenal Medulla	(23)	(22)
Lymphoma Malignant	1 (4%)	
Pheochromocytoma Benign	1 (4%)	
Islets, Pancreatic	(23)	(23)
Parathyroid Gland	(23)	(23)
Pituitary Gland	(23)	(23)
Lymphoma Malignant		
Thyroid Gland	(23)	(23)

GENERAL BODY SYSTEM

Tissue NOS	(0)	(0)
Abdominal, Sarcoma		
Thoracic, Histiocytic Sarcoma		

GENITAL SYSTEM

Epididymis	(23)	(23)
Sarcoma, Metastatic, Uncertain Primary Site		
Preputial Gland	(23)	(23)
Squamous Cell Carcinoma	1 (4%)	
Squamous Cell Papilloma		1 (4%)
Prostate	(23)	(23)
Seminal Vesicle	(23)	(23)
Sarcoma, Metastatic, Uncertain Primary Site		
Testes	(23)	(23)

HEMATOPOIETIC SYSTEM

Bone Marrow	(23)	(23)
Leukemia Granulocytic		
Lymphoma Malignant		1 (4%)
Lymph Node	(1)	(1)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20310 - 03

Test Type: 26-39 WEEKS

Route: GAVAGE

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

AZT+3TC combination

CAS Number: AZT3TCCOMBO

Date Report Requested: 05/04/2010

Time Report Requested: 13:35:32

First Dose M/F: 12/22/06 / NA

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE AZT40,3TC25,NVP7 A60,3T37.5,N10.5

Sarcoma, Metastatic, Uncertain Primary Site		
Axillary, Lymphoma Malignant	1 (100%)	
Cervical, Lymphoma Malignant		
Inguinal, Lymphoma Malignant	1 (100%)	
Lumbar, Leukemia Granulocytic		
Lumbar, Lymphoma Malignant	1 (100%)	
Mediastinal, Lymphoma Malignant		1 (100%)
Mediastinal, Sarcoma, Metastatic, Tissue Nos		
Mediastinal, Sarcoma, Metastatic, Uncertain Primary Site		
Pancreatic, Lymphoma Malignant		
Popliteal, Leukemia Granulocytic		
Popliteal, Lymphoma Malignant	1 (100%)	
Renal, Lymphoma Malignant	1 (100%)	1 (100%)
Lymph Node, Mandibular	(23)	(23)
Leukemia Granulocytic		
Lymphoma Malignant	1 (4%)	1 (4%)
Lymph Node, Mesenteric	(23)	(23)
Leukemia Granulocytic		
Lymphoma Malignant	1 (4%)	1 (4%)
Sarcoma, Metastatic, Tissue Nos		
Sarcoma, Metastatic, Uncertain Primary Site		
Spleen	(23)	(23)
Hemangiosarcoma		
Leukemia Granulocytic		
Lymphoma Malignant	1 (4%)	2 (9%)
Thymus	(20)	(20)
Leukemia Granulocytic		
Lymphoma Malignant	1 (5%)	1 (5%)
Sarcoma, Metastatic, Uncertain Primary Site		

INTEGUMENTARY SYSTEM

Skin	(23)	(24)
Lymphoma Malignant		1 (4%)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20310 - 03

Test Type: 26-39 WEEKS

Route: GAVAGE

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

AZT+3TC combination

CAS Number: AZT3TCCOMBO

Date Report Requested: 05/04/2010

Time Report Requested: 13:35:32

First Dose M/F: 12/22/06 / NA

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE	AZT40,3TC25,NVP7	A60,3T37.5,N10.5
---------------------------------------	------------------	------------------

Osteosarcoma, Metastatic, Bone		1 (4%)
Squamous Cell Papilloma	1 (4%)	

MUSCULOSKELETAL SYSTEM

Bone	(1)	(1)
Osteosarcoma		
Cranium, Neuroblastoma, Metastatic, Nose	1 (100%)	
Cranium, Osteosarcoma		
Humerus, Osteosarcoma		
Pelvis, Osteosarcoma		
Rib, Osteosarcoma		1 (100%)
Tibia, Osteosarcoma		
Bone, Femur	(23)	(24)
Osteosarcoma		
Skeletal Muscle	(0)	(0)
Leiomyosarcoma, Metastatic, Intestine Small, Duodenum		
Lymphoma Malignant		
Rhabdomyosarcoma		
Diaphragm, Sarcoma, Metastatic, Tissue Nos		
Diaphragm, Sarcoma, Metastatic, Uncertain Primary Site		

NERVOUS SYSTEM

Brain, Brain Stem	(23)	(23)
Lymphoma Malignant		
Brain, Cerebellum	(23)	(23)
Lymphoma Malignant		
Brain, Cerebrum	(23)	(23)
Leukemia Granulocytic		
Lymphoma Malignant		
Olfactory Lobe, Neuroblastoma, Metastatic, Nose	1 (4%)	

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20310 - 03

Test Type: 26-39 WEEKS

Route: GAVAGE

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

AZT+3TC combination

CAS Number: AZT3TCCOMBO

Date Report Requested: 05/04/2010

Time Report Requested: 13:35:32

First Dose M/F: 12/22/06 / NA

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE	AZT40,3TC25,NVP7	A60,3T37.5,N10.5
---------------------------------------	------------------	------------------

Spinal Cord, Thoracic	(0)	(0)
-----------------------	-----	-----

RESPIRATORY SYSTEM

Lung	(23)	(23)
Alveolar/Bronchiolar Adenoma	2 (9%)	
Alveolar/Bronchiolar Carcinoma		
Histiocytic Sarcoma		
Lymphoma Malignant	1 (4%)	1 (4%)
Osteosarcoma, Metastatic, Bone		
Nose	(23)	(24)
Lymphoma Malignant		
Neuroblastoma	1 (4%)	
Osteosarcoma		

SPECIAL SENSES SYSTEM

Eye	(23)	(23)
Harderian Gland	(23)	(23)
Adenoma		
Carcinoma		
Neuroblastoma, Metastatic, Nose	1 (4%)	

URINARY SYSTEM

Kidney	(23)	(23)
Leukemia Granulocytic		
Lymphoma Malignant	1 (4%)	
Capsule, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		
Urinary Bladder	(23)	(23)
Sarcoma		

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

TDMS No. 20310 - 03

Test Type: 26-39 WEEKS

Route: GAVAGE

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

AZT+3TC combination

CAS Number: AZT3TCCOMBO

Date Report Requested: 05/04/2010

Time Report Requested: 13:35:32

First Dose M/F: 12/22/06 / NA

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE

AZT40,3TC25,NVP7

A60,3T37.5,N10.5

SYSTEMIC LESIONS

Multiple Organ

*(23)

*(24)

Histiocytic Sarcoma

Leukemia Granulocytic

Lymphoma Malignant

1 (4%)

2 (8%)

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

TDMS No. 20310 - 03

Test Type: 26-39 WEEKS

Route: GAVAGE

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

AZT+3TC combination

CAS Number: AZT3TCCOMBO

Date Report Requested: 05/04/2010

Time Report Requested: 13:35:32

First Dose M/F: 12/22/06 / NA

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE	Vehicle	AZT 60	3TC 37.5	NVP 10.5	AZT 60 3TC 37.5	A20,3T12.5,NV3.5
---------------------------------------	---------	--------	----------	----------	-----------------	------------------

Tumor Summary for Males

Total Animals with Primary Neoplasms (b)	7	13	9	9	17	11
Total Primary Neoplasms	9	16	10	10	17	12
Total Animals with Benign Neoplasms	1	8	5	5	9	7
Total Benign Neoplasms	1	8	5	5	9	8
Total Animals with Malignant Neoplasms	7	7	5	5	8	4
Total Malignant Neoplasms	8	8	5	5	8	4
Total Animals with Metastatic Neoplasms	3		2			
Total Metastatic Neoplasms	8		14			
Total Animals with Malignant Neoplasms Uncertain Primary Site			1			
Total Animals with Neoplasms Uncertain- Benign or Malignant						
Total Uncertain Neoplasms						

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

TDMS No. 20310 - 03

Test Type: 26-39 WEEKS

Route: GAVAGE

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

AZT+3TC combination

CAS Number: AZT3TCCOMBO

Date Report Requested: 05/04/2010

Time Report Requested: 13:35:32

First Dose M/F: 12/22/06 / NA

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE

AZT40,3TC25,NVP7

A60,3T37.5,N10.5

Tumor Summary for Males

Total Animals with Primary Neoplasms (b)	13	14
Total Primary Neoplasms	16	14
Total Animals with Benign Neoplasms	11	10
Total Benign Neoplasms	11	10
Total Animals with Malignant Neoplasms	5	4
Total Malignant Neoplasms	5	4
Total Animals with Metastatic Neoplasms	1	1
Total Metastatic Neoplasms	3	1
Total Animals with Malignant Neoplasms Uncertain Primary Site		
Total Animals with Neoplasms Uncertain- Benign or Malignant		
Total Uncertain Neoplasms		

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors